

30 October 2023

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 21/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of November 2023 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

The decisions were as follows (deletions to presentation in strikethrough, additions in **bold**):

1. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Nicorandil ¹	Tab 10 mg; 60 tablet blister pack	\$25.57	\$21.73	Max Health (Max Health)	1 December 2023	1 May 2024	Ikorel (Sanofi-AU)
Nicorandil ¹	Tab 20 mg; 60 tablet blister pack	\$32.28	\$27.44	Max Health (Max Health)	1 December 2023	1 May 2024	Ikorel (Sanofi-AU)
¹ Brand switch fee of \$4.50 is payable for this product from 1 May 2024 to 31 July 2024							

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule

The decisions were as follows (deletions to presentation in strikethrough, additions in **bold**):

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of price change	Principal Supply date	Brand (Supplier) affected by delisting
Nicorandil	Tab 10 mg; 60 tablet blister pack	\$25.57	\$21.73	Max Health (Max Health)	5%	1 December 2023	1 May 2024	Ikorel (Sanofi-AU)

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of price change	Principal Supply date	Brand (Supplier) affected by delisting
Nicorandil	Tab 20 mg; 60 tablet blister pack	\$32.28	\$27.44	Max Health (Max Health)	5%	1 December 2023	1 May 2024	Ikorel (Sanofi-AU)
Nimodipine	Inj 200 mcg 0.2 mcg per ml, 50 ml vial; 5 vial pack	\$337.50	\$337.50	Nimotop (Pharmacode 2663937) (Bayer)	5%	1 December 2023	1 May 2024	Nimotop (Pharmacode 818453) (Bayer)

2022/23 Tender – Principal Supply Status applies until 30 June 2026

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

3. *Tenders awarded to pharmaceuticals where no other brand is listed.*

Chemical name	Presentation; Pack size and type	Pack price	Principal Supply brand (Supplier)	DV limit	Listing date	Principal Supply date
Ephedrine	Inj 3 mg per ml, 10 ml syringe; 10 syringe pack	\$142.00	Ephedrine Juno (Juno)	5%	1 January 2024	1 June 2024

Tender declines - Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the:

- 2021/22 Invitation to Tender, dated 1 November 2021
- 2022/23 Invitation to Tender dated 31 October 2022

2021/22 Invitation to Tender

Chemical name	Line item
Acetazolamide	Tab 250 mg
Amisulpride	Tab 100 mg
Amisulpride	Tab 200 mg
Amisulpride	Tab 400 mg
Amoxicillin with clavulanic acid	Grans for oral liq 125 mg with potassium clavulante 31.25 mg per 5 ml
Amoxicillin with clavulanic acid	Grans for oral liq 250 mg with potassium clavulante 62.5 mg per 5 ml
Cetomacrogol with glycerol	Crn 90% with glycerol 10%, 100 g
Ertapenem	Inj 1 g vial

Chemical name	Line item
Haloperidol	Inj 5 mg per ml, 1 ml
Levosimendan	Inj 2.5 mg per ml, 5 ml
Medroxyprogesterone	Inj long-acting 150 mg per ml, 1 ml syringe
Pemetrexed	Inj 100 mg
Pemetrexed	Inj 500 mg
Sodium hyaluronate [hyaluronic acid]	Inj 30 mg per ml
Tenecteplase	Inj 50 mg
Tranlycypromine sulphate	Tab 10 mg

2022/23 Invitation to Tender

Chemical name	Line item
Fosfomycin (current access)	Powder
Fosfomycin (widened access)	Powder
Hyoscine N-butylbromide	Tab 10 mg
Metaraminol tartrate	Inj 0.5 mg per ml, 10 ml

Chemical name	Line item
Metaraminol tartrate	Inj 0.5 mg per ml, 5 ml
Noradrenaline	Inj 0.06 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.1 mg per ml, 50 ml syringe

For products included in the 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.